Study Comparing Treatment With Alluzience vs Reconstituted Toxin

Phase 4 Completed 150 enrolled Galderma R&D

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).

Timeline

Start: 2022-02-04
Primary completion: 2022-10-12
Completion: 2022-10-12

Publications

Chadha P, Gerber PA, Hilton S, Molina B, Haq S, Partridge J, Wong V, Hoffmann K, Persson C, Prygova I. Ready-to-use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study. J Cosmet Dermatol. 2024 Sep;23(9):2857-2866. doi: 10.1111/jocd.16359. Epub 2024 May 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alluzience	Unknown	50 iu	Intramuscular
Comparator	Botulinum toxin type A	Protein / enzyme biologic	20 iu	Intramuscular

Indications

No indication recorded.